Laura Joszt, MA

Laura Joszt headshot

Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences®, which includes The American Journal of Managed Care®, Managed Healthcare Executive®, Pharmacy Times®, and Drug Topics®. She has been with MJH Life Sciences since 2011.

Laura has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.

Articles by Laura Joszt, MA

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.

In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.

Panelists at the Office of the National Coordinator for Health Information Technology (IT)’s Annual Meeting discussed their perspectives on health IT innovation and expectations for 2018.

Researchers examined the gut microbiome of patients with metastatic melanoma who were being treated with anti–PD-1 immunotherapy, and they determined that patients with a more diverse population of gut bacteria or an abundance of certain types of bacteria were more likely to have their disease controlled for longer.

From 1999-2000 to 2015-2016, there has been a declining trend in high total cholesterol among adults in the United States, according to a report from the CDC. From 2007-2008 to 2015-2016 there was also a decline in low high-density cholesterol. Both types of cholesterol are risk factors for cardiovascular disease, which remains the leading cause of death in the United States.

While it is known that febrile neutropenia is the most common reason for pediatric patients with cancer visiting the emergency department (ED), little had been known about the most common reasons for adult patients with cancer ending up in the ED.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo